CVI Email Content Delivery
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, X.
Right arrow Articles by Cao, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, X.
Right arrow Articles by Cao, C.
Clinical and Diagnostic Laboratory Immunology, January 2004, p. 227-228, Vol. 11, No. 1
1071-412X/04/$08.00+0     DOI: 10.1128/CDLI.11.1.227-228.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Profile of Antibodies to the Nucleocapsid Protein of the Severe Acute Respiratory Syndrome (SARS)-Associated Coronavirus in Probable SARS Patients

Xuan Liu,1 Yulin Shi,2 Ping Li,1 Linhai Li,2 Yanping Yi,1 Qingjun Ma,1 and Cheng Cao1*

Beijing Institute of Biotechnology, Beijing 100850,1 General Hospital of Guangzhou Command of PLA, Guangzhou 510010, Peoples Republic of China2

Received 25 August 2003/ Returned for modification 28 October 2003/ Accepted 5 November 2003

Profiles of antibodies to the nucleocapsid protein of the severe acute respiratory syndrome (SARS)-associated coronavirus in 445 probable SARS patients and 3,749 healthy people or non-SARS patients were analyzed by antigen-capturing enzyme-linked immunosorbent assay. Antinucleocapsid antibodies were elucidated in 17.5% of the probable SARS patients 1 to 7 days after the onset of symptoms and in 80% of the patients 8 to 14 days after the onset. About 90% of the probable SARS patients were positive 15 or more days after illness. Antibody titers increased up to 70 days, and high antibody titers were maintained at least for another 3 months. Of the healthy people and non-SARS patients, only seven (0.187%) were weakly positive.


* Corresponding author. Mailing address: Beijing Institute of Biotechnology, P.O. Box 130(8), 27 Taiping Rd., Beijing 100850, Peoples Republic of China. Phone and fax: 86 10 68155151. E-mail: caoc{at}nic.bmi.ac.cn.


Clinical and Diagnostic Laboratory Immunology, January 2004, p. 227-228, Vol. 11, No. 1
1071-412X/04/$08.00+0     DOI: 10.1128/CDLI.11.1.227-228.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2004 by the American Society for Microbiology. All rights reserved.